Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this randomized, double blind, double dummy, multicenter study was to evaluate the efficacy of risperidone long-acting injectable (LAI) monotherapy in comparison with placebo in the pre...
Detailed Description
This is a randomized, double-blind, double-dummy multicenter study with 3 parallel arms (risperidone long-acting injectable (LAI), placebo, and olanzapine) to evaluate the efficacy and safety of rispe...
Eligibility Criteria
Inclusion
- Diagnosis of bipolar I disorder as defined by DSM-IV-TR criteria. All diagnoses will be confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.). Patients who present with additional signs or symptoms compatible with Axis I diagnoses of social anxiety disorder or generalized anxiety disorder are acceptable. All other comorbid or active Axis I diagnoses are excluded. Personality disorders as defined by DSM IV TR criteria are acceptable, with the exception of antisocial and borderline personality disorders
- Must be currently experiencing a manic or mixed episode (acute
- YMRS \>20 and CGI-S =\>4 \[moderate\]) or must be between mood episodes (non-acute
- YMRS \<12 and CGI-S=\<3 \[mild\])
- Must have had at least 2 bipolar mood (manic, mixed manic, or depressed) episodes, exclusive of the current episode (if applicable), during the last year. For non-acute subjects (YMRS \<12 and CGI-S=\<3 \[mild\]), one manic episode must have occurred within 4 months of enrollment
- Patients who are non-acute (YMRS \<12 and CGI-S =\<3 \[mild\]) and are currently receiving an antipsychotic other than risperidone or a mood stabilizer must have received this other medication at the same dosage for a minimum of 4 weeks and must be either experiencing problems of safety or tolerability with the antipsychotic or mood stabilizer or request a change of medication
Exclusion
- No history of more than 4 mood episodes each year (rapid cycling) during the last 2 years prior to screening
- No history of ADHD, anxiety disorder, or panic disorder as the primary diagnosis
- Not meeting DSM-IV-TR criteria for a hypomanic or depressive episode
- Not meeting DSM-IV-TR criteria for any comorbid or active Axis I disorder other than those specifically allowed in the Inclusion Criteria
- Not meeting DSM-IV-TR criteria for antisocial or borderline personality disorder
- Not having a chronic or serious general medical illness, including hepatic, renal, respiratory, cardiovascular, endocrine, neurologic (including seizure disorder), or hematologic disease as determined by the clinical judgment of the investigator
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
585 Patients enrolled
Trial Details
Trial ID
NCT00391222
Start Date
November 1 2006
End Date
April 1 2009
Last Update
May 9 2014
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Baoding, China
2
Beijing, China
3
Guangzhou, China
4
Nanjing, China